Clinical Trials · NCT00975286

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Name: 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lixisenatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 446
Start date: Oct 2009
Locations: 140 sites, 26 countries
Primary endpoint: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

View Lixisenatide compound reference